<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Taba">
 <table frame="hsides" rules="groups">
  <tbody>
   <tr>
    <td align="left">Immune dysregulation in COVID-19 infection includes suppression of adaptive but hyperactivation of innate immune system.</td>
   </tr>
   <tr>
    <td align="left">Hypercoagulability combined with endotheliitis and hyperinflammation results in significant incidence of pulmonary microvascular thrombosis.</td>
   </tr>
   <tr>
    <td align="left">Aggressive prophylactic anticoagulation strategy is likely to be effective in sick patients in preventing thrombosis and improving outcome.</td>
   </tr>
   <tr>
    <td align="left">Clinical and laboratory biomarker of disease severity will help to identify who will benefit from combination of antiviral, anti inflammatory and anticoagulation drugs.</td>
   </tr>
   <tr>
    <td align="left">Urgent international collaboration is necessary to run large trials to find which drugs and in what combination will be most effective in treating COVID-19 patients.</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
